TD Asset Management Inc Sells 45,407 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

TD Asset Management Inc lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 441,177 shares of the biopharmaceutical company’s stock after selling 45,407 shares during the period. TD Asset Management Inc’s holdings in Alnylam Pharmaceuticals were worth $143,863,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bessemer Group Inc. increased its position in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares during the last quarter. Crossmark Global Holdings Inc. bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $275,000. Strs Ohio bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $7,781,000. GAMMA Investing LLC increased its position in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 77 shares during the last quarter. Finally, Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research reports. Evercore ISI boosted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Needham & Company LLC boosted their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Royal Bank Of Canada lifted their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a research note on Friday, September 19th. Finally, Barclays lifted their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Twenty-four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $457.08.

Alnylam Pharmaceuticals Stock Up 0.9%

Shares of ALNY opened at $469.36 on Wednesday. The firm has a market capitalization of $61.52 billion, a P/E ratio of -190.02 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $484.21. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a fifty day moving average price of $453.28 and a 200-day moving average price of $348.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The firm had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business’s revenue was up 17.3% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the transaction, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president owned 25,231 shares of the company’s stock, valued at $11,405,673.55. This represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock valued at $44,160,261 over the last three months. 1.20% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.